Back
Primary central nervous system lymphoma: Novel precision therapies.
Journal article

Primary central nervous system lymphoma: Novel precision therapies.

  • Mondello P Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, 413 East 69th Street, 10021 New York, NY, USA; Department of Human Pathology, University of Messina,Via Consolare Valeria, 98125 Messina, Italy. Electronic address: pam2068@med.cornell.edu.
  • Mian M Department of Hematology & CBMT, Ospedale di Bolzano, Via Lorenz Böhler, 5, 39100 Bolzano, Italy.
  • Bertoni F Università della Svizzera italiana, Institute of Oncology Research, Via Vela 6, 6500 Bellinzona, Switzerland.
  • 2019-07-12
Published in:
  • Critical reviews in oncology/hematology. - 2019
CAR T-cell
Ibrutinib
Lenalidomide
Nivolumab
PCNSL
Precision therapies
Rituximab
Temsirolimus
Antineoplastic Combined Chemotherapy Protocols
Central Nervous System Neoplasms
High-Throughput Nucleotide Sequencing
Humans
Immunotherapy
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
Methotrexate
Molecular Targeted Therapy
Precision Medicine
Therapies, Investigational
English Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of diffuse large B-cell lymphoma. The frontline treatment with high-dose methotrexate based immunochemotherapy is not curative for the majority of patients. Gene expression profiling and next-generation sequencing have recently provided plethora of data shedding light on pathogenic mechanisms sustain PCNSL and identifying potential vulnerable mechanisms to be explored therapeutically. Here, we review established molecular drivers of PCNSL and targeted drugs that may change the current therapeutic paradigm.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/19835
Statistics
Document views: 38 File downloads: